Showing results (11-20 of 320) with videos related to

Sort By:
Pageof 32
Cancer Research|February 15, 1992
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemiaV Gandhi, A Kemena, M J Keating, et al.
Leukemia|September 1, 1994
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemiaV Gandhi, M Du, H M Kantarjian, et al.
Blood|November 1, 1989
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapyV Gandhi, B Nowak, M J Keating, et al.
Seminars in Oncology|October 1, 1996
Gemcitabine: preclinical pharmacology and mechanisms of actionW Plunkett, P Huang, C E Searcy, et al.
Leukemia & Lymphoma|January 1, 1993
Biochemical modulation of arabinosylcytosine for therapy of leukemiasV Gandhi, E Estey, M J Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion scheduleJ F Seymour, P Huang, W Plunkett, et al.
Leukemia & Lymphoma|May 1, 1993
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapyV Gandhi, A Kemena, M J Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapyV Gandhi, E Estey, M J Keating, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacologyV Gandhi, L E Robertson, M J Keating, et al.
Blood|January 1, 1996
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactionsV Gandhi, E Estey, M J Keating, et al.
Pageof 32